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Abstract
Background: Female mice and rats injected with estrogen perinatally become anovulatory and
develop follicular cysts. The current consensus is that this adverse response to estrogen involves
the hypothalamus and occurs because of an estrogen-induced alteration in the GnRH delivery
system. Whether or not this is true has yet to be firmly established. The present study examined
an alternate possibility in which anovulation and cyst development occurs through an estrogen-
induced disruption in the immune system, achieved through the intermediation of the thymus gland.
Methods, Results and Conclusion: A putative role for the thymus in estrogen-induced
anovulation and follicular cyst formation (a model of PCOS) was examined in female mice by
removing the gland prior to estrogen injection. Whereas all intact, female mice injected with 20 ug
estrogen at 5–7 days of age had ovaries with follicular cysts, no cysts were observed in animals in
which thymectomy at 3 days of age preceded estrogen injection. In fact, after restoring immune
function by thymocyte replacement, the majority of thymectomized, estrogen-injected mice had
ovaries with corpora lutea. Thus, when estrogen is unable to act on the thymus, ovulation occurs
and follicular cysts do not develop. This implicates the thymus in the cysts' genesis and discounts
the role of the hypothalamus. Subsequent research established that the disease is transferable by
lymphocyte infusion. Transfer took place between 100-day-old estrogen-injected and 15-day-old
naïve mice only when recipients were thymectomized at 3 days of age. Thus, a prerequisite for cyst
formation is the absence of regulatory T cells. Their absence in donor mice was judged to be the
result of an estrogen-induced increase in the thymus' vascular permeability, causing de facto
circumvention of the final stages of regulatory T cell development. The human thymus has a similar
vulnerability to steroid action during the fetal stage. We propose that in utero exposure to
excessive levels of steroids such as estrogen has a long-term effect on the ability of the thymus to
produce regulatory T cells. In female offspring this can lead to PCOS.
Published: 18 May 2009
Reproductive Biology and Endocrinology 2009, 7:47 doi:10.1186/1477-7827-7-47
Received: 7 April 2009
Accepted: 18 May 2009
This article is available from: http://www.rbej.com/content/7/1/47
© 2009 Chapman et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Reproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
Page 2 of 11
(page number not for citation purposes)
Background
Polycystic ovarian syndrome (PCOS) occurs in 5%–10%
of all women of reproductive age [1,2]. The disease begins
at menarche, and symptoms generally include oligomen-
horrhea, amenorrhea, anovulation, cystic ovaries, an ele-
vated LH/FSH ratio, obesity, hirsutism, and insulin
resistance. Cystic ovaries produce high levels of andros-
tenedione, testosterone, and 17αOH-progesterone. The
cysts themselves are remnants of atretic follicles, fluid
filled and devoid of granulosa cells. As reported in the sci-
entific literature in 1935 [3] the etiology of PCOS still
remains obscure. Three major hypotheses are [4]: 1)
PCOS is due to a primary neuroendocrine defect leading
to an exaggerated LH pulse frequency and amplitude; 2)
the disease is caused by a deficiency in insulin action lead-
ing to hyperinsulinemia; and 3) the primary fault occurs
in the ovary and involves changes in FSH response.
Basic symptoms of PCOS such as anovulation and follic-
ular cysts are produced in female mice by injecting them
with estrogen, testosterone, or cortisone prior to 10-days
of age [5,6]. Significantly, during this same 10-day period
the thymus gland is in its final stages of development.
Interference with this process alters the evolution of 'self'
versus 'nonself' recognition [7]. For example, thymectomy
at 3-days of age prevents the production of regulatory T
cells, and a number of autoimmune diseases ensue [8,9].
Evidence presented herein suggests that steroids also fore-
stall the production of regulatory T cells. The resultant
autoimmune disease in this instance is PCOS.
Methods
Animals and reagents
Female (C57Bl/6J × A/J)F1 (B6A) mice were used in the
study. Parental stocks were purchased from Jackson Labo-
ratory, Bar Harbor, ME. All mice were maintained in our
animal care facility and cared for in accordance with insti-
tutional guidelines. Sesame oil, steroid hormones, Hanks
balanced salt solution (HBSS), and Trypan Blue were pur-
chased from Sigma Chemical Company; St. Louis, Mis-
souri, USA. Lympholyte M was purchased from Cedarlane
Laboratories, Ontario, Canada. All other reagents were
purchased from Fisher Scientific, Hampton, NH.
Treatments
Steroid injection
Neonatal B6A female mice were injected subcutaneously
(sc) with 0.010 ml sesame oil:ethanol (9:1; v:v) (vehicle),
or vehicle containing 20 μg of either estradiol-17β, testo-
sterone, cortisol, or progesterone; or vehicle containing 10
μg diethlystilbestrol (DES).
Thymocyte infusion
Thymocytes were prepared from thymuses taken from
mice killed by etherization. After weighing the thymus it
was pressed between two glass slides and connective tis-
sue teased away and discarded. The thymocytes were then
suspended in 4 ml HBSS and centrifuged at 1000 × g for
10 min at 22°C. Following a second wash and recentrifu-
gation, the cells were resuspended in 4 ml of HBSS and
counted with a hemocytometer. The thymocyte suspen-
sion was then recentrifuged and the pellet resuspended in
HBSS. Total volume of the suspension was adjusted to
allow for an infusion of 20 million thymocytes per 0.10
ml HBSS. The infusions were administered to 15-day-old
Tx-3 pups via a 1 ml plastic syringe outfitted with a 0.5
inch, 27 gauge needle inserted just above the "navel". The
infusion site was subsequently covered with skin-bond
adhesive. Immature female thymocyte donors were 7 days
of age, and mature female thymocyte donors ranged from
60 days to 120 days of age.
Lymphocyte infusion
Splenocytes were isolated from spleens removed from
decapitated female donors. Each spleen was weighed and
placed on a stainless steel wire mesh (0.65 mm × 0.65
mm) suspended over a glass beaker. Using the rubber end
of a 5 ml plastic syringe plunger, the spleen was mashed
and the sheath discarded. The resultant splenocytes were
washed from the mesh, and centrifuged at 250 × g for 10
min at 22°C. Subsequent treatments depended on the
individual study. When splenocytes were used for count-
ing, the pellet was resuspended in 3 ml HBSS; however,
when prepared for infusion, the splenocyte pellet was
resuspended in 12 ml HBSS. The suspension was then
apportioned between two 15 ml conical plastic test tubes.
Two ml of Lympholyte M were added to the bottom of
each tube, and lymphocytes separated from erythrocytes
by centrifugation at 1200 × g for 20 min at 22°C. Lym-
phocytes were recovered and suspended in 6 ml of HBSS
and centrifuged at 250 × g for 10 min at 22°C. The lym-
phocyte pellet was resuspended in 3 ml of HBSS and
counted with a hemocytometer. The suspension was
recentrifuged and the pellet resuspended in HBSS. The
total volume was adjusted to allow for an infusion of 20
million lymphocytes per 0.10 ml HBSS. Lymphocyte infu-
sions were administered to 15-day-old Tx-3 pups as
described for thymocyte infusions. Estrogen-injected
female donors ranged from 100 days to 110 days of age.
Cell counting
Cells were counted using the Trypan Blue Exclusion Test.
For this procedure, 0.010 ml was removed from the 3 ml
(splenocyte) and 4 ml (thymocyte) stock suspensions and
added to a microcentrifuge tube containing 0.080 ml of
HBSS and 0.010 ml of Trypan Blue dye. Viable cells were
enumerated in a hemocytometer with the aid of a light
microscope. Two quadrants were averaged for each sam-
ple. In general, there were few cells that did not excludeReproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
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Trypan Blue, indicating the efficiency of the procedure in
producing viable cells.
Sacrifice, sample collection, and histology
After light etherization, the mice were killed by decapita-
tion. Unless otherwise stated, all experimental animals
were killed between 100 and 110 days of age. Ovaries
were collected, placed in Bouins fixative for 24 hr, and
then stored in 70% ethanol. Fixed ovaries were cleaned of
adherent fat, weighed, and embedded in paraffin. After-
wards, they were sectioned at 5 μm, placed on a glass slide,
and stained with Harris's hematoxylin and eosin Y.
Stained sections were examined via light microscopy for
the presence of follicular cysts, corpora lutea (CLs), and
for ovarian dysgenesis. Ovaries were classified according
to state of reproductive ability. For example, ovaries that
contained follicles and CLs were considered to be from
fertile mice. Ovaries that lacked CLs, and contained follic-
ular cysts were considered to be from infertile mice. Ova-
ries that lacked CLs and follicles were deemed to be
dysgenic.
Other procedures
Thymectomy was performed on day 3 (Tx-3) by aspira-
tion, as previously described [10]. Statistical analyses were
performed on all experiments having multiple replicates,
using ANOVA and the Student t test. All data are reported
as mean ± standard error of the mean (S.E.M.).
Results and discussion
Our first study (Table 1) was undertaken to determine if
removing the thymus prior to estrogen injection could
prevent anovulation and follicular cysts. Mice were
thymectomized on day 3 (Tx-3) [10], and at 5–7 days of
age given daily injections of estradiol-17β (E2) (Treatment
7); the thymus was essentially replaced after steroid treat-
ment by infusing the Tx-3 animals on day 15 with 20 ×
106 thymocytes from adult female donors [11]. Whereas
all intact, 100-day-old female mice injected with E2 at 5–
7 days of age (Treatment 2) had ovaries containing follic-
ular cysts, none were observed in 100-day-old Treatment
7 animals in which thymectomy preceded E2 injection. In
fact, the majority had ovaries with corpora lutea (CLs).
Thus, when E2 is unable to act on the thymus, ovulation
occurs and follicular cysts do not develop. This implicates
the thymus in the cysts' genesis. Note that infusion of thy-
mocytes from 7-day-old females neither prevented cysts
(Treatment 5), nor restored immunocompetency to Tx-3
mice (Treatment 4). The reason for this will be discussed
later.
Table 1: The prevention of follicular cysts in estrogen-injected (C57BL/6J × A/J) F1 (B6A) female mice by thymectomy and thymocyte 
replacement.
Condition of Ovaries
Treatment CLs Dysgenic Cysts Other
1. Sesame oil Days 5–7 [8]a 100%b
(14.7 ± 1.4)c
------ ------ ------
2. E2 Days 5–7 [17] ------ ------ 100%
(10.8 ± 0.3)
------



















6. Tx-3 + thymocytes from adult females [18] 100%
(9.9 ± 0.6)
------ ------ ------




Mice in treatments (1) and (2) were injected sc at 5–7 days of age with either sesame oil: ethanol (9:1; v:v) {vehicle}, or vehicle containing 20 μg 
estradiol-17β (E2). In treatment (3), the females were thymectomized at 3 days of age (Tx-3). Treatments (4) and (6) consisted of infusing 15-day-
old Tx-3 mice with 20 million thymocytes, isolated from thymuses of either 7-day-old or adult female B6A donors. In treatments (5) and (7), Tx-3 
females were injected with E2 at 5–7 days of age, and then infused with 20 million thymocytes, isolated from thymuses of either 7-day-old or adult 
female B6A donors. All recipient females were killed at 100 days of age and ovaries removed and examined histologically for corpora lutea (CLs), 
follicular cysts, and dysgenesis. Normal ovaries contained normal follicle populations and CLs. Dysgenic ovaries lacked all follicle populations. Cystic 
ovaries contained follicular cysts, and lacked CLs.
aNumber of animals in each group.
bPercentage of animals with similar ovarian histology.
cAverage weight of paired fixed ovaries (mg ± S.E.M.).
dOvaries with cysts and CLs.
eDysgenic ovaries with cysts.
fOvaries with normal follicle populations, but lacking both CLs and follicular cysts.Reproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
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Study 2 demonstrated the ability of lymphocytes from E2-
injected mice to create follicular cysts when infused into
Tx-3 animals. Female mice, injected at 5–7 days of age
with either E2 or diethylstilbestrol (DES), were killed at
100–110 days of age, and their lymphocytes (isolated
from spleens) infused into 15-day-old, Tx-3 females. Con-
trol Tx-3 mice were given lymphocytes from vehicle-
injected animals. Recipients were killed at 100 days of age,
and ovaries from both donor and recipient mice exam-
ined for the presence of follicular cysts and CLs. All ova-
ries from E2-injected (n = 10) and DES-injected (n = 20)
donor-animals had follicular cysts; none had CLs. Seven
of 10 of recipient mice infused with lymphocytes from E2-
injected animals, and 11 of 20 infused with lymphocytes
from DES-injected animals, had ovaries containing follic-
ular cysts. Taken in toto a reasonable explanation for these
results is that the infusate from the E2- and DES-injected
animals contained autoreactive T cells, but lacked regula-
tory T cells; a combination that led to the creation of cysts
in the recipient Tx-3 mice. The absence of cysts in some
Tx-3 recipients is likely due to incomplete thymectomy.
Thymic fragments are fully capable of producing regula-
tory T cells, as we have previously reported [12]. No cysts
were seen in the ovaries of Tx-3 mice infused with lym-
phocytes from vehicle-injected animals. Figure 1 contains
photomicrographs of ovaries from: (A) vehicle-injected
donor and (B) Tx-3 recipient mice; (C) E2-injected donor
and (D) Tx-3 recipient mice; and, (E) DES-injected donor
and (F) Tx-3 recipient mice. Note CLs in photomicro-
graphs A and B and their absence in photomicrographs C
through F.
The remaining studies determined the role of steroids in
altering the ability of the thymus to produce regulatory T
cells. Normally, thymocytes do not exit the thymus until
they become mature T cells. However, estrogen is reported
to increase the gland's vascular permeability [13]. This
could cause early thymocyte discharge and contravene
production of regulatory T cells. Female mice were
injected at 5–7 days of age with E2, testosterone (T), corti-
sol, or progesterone. At 12-days of age they were killed,
thymuses and spleens removed and weighed, and thymo-
cytes and splenocytes counted. Mice injected with E2 had
50 million fewer thymocytes than control animals (p <
0.025) (Table 2). Mice injected with cortisol and proges-
terone had 30 million and 10 million fewer thymocytes,
respectively (N.S.). Notably, animals injected with T had
increased numbers of thymocytes. This was unexpected
and necessitated a more detailed assessment of the effect
of T on the thymus; for comparison, a similar analysis was
made of the effect of E2.
Female mice were injected at 5–7 days of age with E2 or at
0–3 days of age with T (T having been shown to have a
slower time course for producing cysts [5]). Beginning 1
day after the last E2 injection and 2 days after T, and at
intervals thereafter, the animals were killed, thymuses
removed and thymocytes counted. Response to E2 was
rapid. Beginning two days after the last injection, thy-
muses of E2-injected animals averaged 50 million fewer
thymocytes than those of control mice (Fig. 2A). Response
to T was quite different (Fig. 2B). Instead of a decrease,
thymocyte levels initially increased, reaching a zenith four
days after the last injection. At this juncture, thymuses of
T-injected mice contained 20 million more thymocytes
than those of control animals. Thymocyte levels subse-
quently fell, and after five days thymuses of T-injected
mice contained 27 million fewer thymocytes than those
of control mice. The slower rate of thymocyte loss, relative
to the rapid loss induced by E2, is reflected in the ability of
each steroid to cause anovulation and follicular cysts. T is
less effective than E2, and produces a "delayed anovula-
tion syndrome" [5,14,15].
In adult mice, thymocyte loss after E2 administration is
unevenly distributed. While the cortex experiences some
loss of thymocytes, the greatest decline occurs in the
medulla [16]. Prior to E2, this region of the thymus con-
tains substantial levels of CD4+CD8+  double positive
(DP) thymocytes and CD4+ and CD8+ T cells. After E2, all
three subsets suffer a 99% reduction. Their lowered levels
reflect a drastically reduced role for the medulla in T cell
development. The loss of thymocytes was interpreted as
being due to a blockage in early T cell development [16].
However, a significant influx in thymocytes precedes any
loss (Fig. 2B). This response is best explained as resulting
from an increase in the thymus' vascular permeability.
Data from Abo [17,18] support this interpretation. In his
study of extrathymic T cell maturation, Abo noted that
sinusoids of mouse liver contain lymphocytes that
increase in number after E2 injection. Their increase occurs
in parallel with thymocyte loss and thymic involution.
FACS analysis reveals them as being a mixed population
of CD4-CD8- double negative (DN) cells with α/β T cell
receptor (TcR), and CD4+ and CD8+ T cells [17]. Since DN
cells are normally found in the cortex of the thymus, their
appearance in the liver suggests a premature exit at, or
near, the corticomedullary junction. Further evidence of a
truncated pathway is indicated by the observation that
estrogen-injected mice have significantly higher spleno-
cyte levels than control animals (Table 3).
Fig. 3A depicts the normal developmental history of CD4+
and CD8+ T cells. Development begins when bone mar-
row precursors enter the thymus at the outer, sub-capsular
region [19]. As the cells then migrate through the cortex
they undergo a number of developmental stages, first as
CD3-CD4-CD8-  triple negative (TN) thymocytes, and
later, after CD3 expression, as DN thymocytes. During
transit the α/β TcR is formed. DN thymocytes express CD4Reproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
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Creation of follicular cysts in Tx-3 female mice by the infusion of lymphocytes from E2- and DES-injected female B6A mice Figure 1
Creation of follicular cysts in Tx-3 female mice by the infusion of lymphocytes from E2- and DES-injected 
female B6A mice. Cross-section of ovary from a 100-day-old mouse (A), given sc injections of 10 μl sesame oil:ethanol (9:1; 
v:v) [vehicle] at 5–7 days of age. Cross-section of ovary from the 100-day-old recipient Tx-3 mouse (B), infused at 15 days of 
age with 20 million lymphocytes, taken from the vehicle-injected animal. Cross-section of ovary from a 100-day-old mouse (C), 
given injections of 20 μg E2 in 10 μl vehicle at 5–7 days of age. Cross-section of ovary from the 100-day-old recipient Tx-3 
mouse (D), infused at 15 days of age with 20 million lymphocytes, taken from the E2-injected animal. Cross-section of ovary 
from a 100-day-old mouse (E), given injections of 10 μg DES in 10 μl vehicle at 5–7 days of age. Cross-section of ovary from 
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and CD8 and, as DP thymocytes, interact with cortical epi-
thelial cells to undergo positive selection. Thymocytes sur-
vive this process if their TcR, along with CD8 and/or CD4
accessory molecules, selectively binds to MHC class I and
class II positive epithelial cells. Surviving DP thymocytes
then pass through the corticomedullary junction into the
medulla, where they undergo negative deletion. The TcR
this time is exposed to self-antigens produced by medul-
lary epithelial cells (MECs). Synthesis of self-antigens,
such as tissue proteins, is under the control of the autoim-
mune regulator (Aire) promoter [20]. It should be noted
that binding of the TcR to self-antigens in conjunction
with MHC class I and class II molecules causes self-
destruction and elimination of most autoreactive T cells.
Regulatory T cells control those that are not eliminated
and that enter into the system. Regulatory T cells comprise
less than 10% of CD4+ T cells, and are identified by their
expression of the CD25 antigen (interleukin-2 receptor α-
chain) [9]. The CD4+CD25+ T cells are unique in that the
binding of their TcR to self-antigens results in activation
and conversion to a nonproliferative (anergic) state
[21,22]. Thus activated they are capable of preventing the
activation of autoreactive CD4+ and CD8+ T cells [21]. All
mature CD4+ and CD8+ T cells exit the thymus at the cor-
ticomedullary junction [19].
Fig. 3B shows the proposed thymocyte maturation path-
way after an increase in thymic vascular permeability. Pro-
thymocytes continue to enter at the outer, sub-capsular
region, and proceed through stages of TN development,
CD3 expression, and formation of the α/β TcR. However,
instead of expressing CD4 and CD8, the majority of
CD3+CD4-CD8- (DN) cells exit at the corticomedullary
junction, bypassing positive selection and negative dele-
tion. Their subsequent development into T cells has been
proposed to occur in the sinusoids of the liver [17,18].
The loss of 50 million thymocytes in E2-injected mice (Fig.
2A) is likely due, in large part, to this altered pathway. The
long-lasting nature of the new pathway is indicated by the
48 million (average) fewer thymocytes found in 60- and
100-day-old perinatally E2-injected mice (Table 3).
The ability of CD4+CD25+ regulatory T cells to exert con-
trol over CD4+
Autoreactive  and CD8+
Autoreactive  T cells is
attained in a region of the thymus (medulla) that is not
fully functional until 7–10 days postpartum [7,19]. Tx-3,
therefore, permanently negates development of
CD4+CD25+  regulatory T cells [9]. E2  administration
achieves this same result. Instead of physical removal of
the thymus, however, E2 initiates an altered thymocyte
maturation pathway and de facto circumvention of the
medulla. The involvement of CD8+
Autoreactive T cells in the
formation of follicular cysts is suggested by the report that
CD8+ T cells selectively infiltrate ovarian tissue during cyst
formation [23]. In a previous study, we made an analysis
of the combined effects of Tx-3 and E2 on ovarian pathol-
ogy [12]. Tx-3 by itself was found to have an incidence of
ovarian dysgenesis, of 45%. The Tx-3 mice having normal
ovaries (55%) were found at autopsy to contain thymic
fragments. A second group, in which E2 was injected after
Tx-3, had a similar efficacy of ovarian dysgenesis (46%).
However, instead of the remaining animals having nor-
mal ovaries, they either had ovaries that were dysgenic
and cystic (39%), or ovaries that were cystic (15%). These
results provided a basic understanding of the sequence in
T cell development, as is diagrammed below.
CD4+
Autoreactive T cells are the first produced by the thymus.
Tx-3 at point A prevents development of CD8+
Autoreactive
cells, TReg CD4 cells, and TReg CD8 cells. This results in ovar-
ian dysgenesis. Tx-3 or E2 administration at point B fore-
stalls development of TReg CD4 cells and TReg CD8 cells. This
CD A CD8 B T C T Autoreactive Autoreactive Reg CD Reg CD 4 48
++ →→ →→ →→
Table 2: The effect of injecting female B6A mice with various steroid hormones at 5–7 days of age on thymus and spleen weights and 









Vehicle [5]a 50.5 ± 3.2b 40.6 ± 3.6 83.0 ± 6.1 33.2 ± 5.9
Progesterone [4] 48.8 ± 3.0 37.4 ± 0.6 73.5 ± 18.1 33.5 ± 1.3
Testosterone [9] 47.8 ± 2.6 46.0 ± 3.6 143.2 ± 25.5 89.2 ± 23.1
Cortisol [13] 26.5 ± 3.4** 27.9 ± 2.0* 52.3 ± 9.2 19.2 ± 3.2
Estradiol-17β [8] 18.5 ± 3.2*** 14.6 ± 1.8*** 33.6 ± 12.0* 5.8 ± 1.1***
Beginning at 5 days of age, mice were given three daily sc injections of 10 μl sesame oil: ethanol (9:1; v:v) {vehicle}, or vehicle containing 20 μg of the 
indicated steroid hormones. At 12 days of age they were killed, thymuses and spleens removed and weighed, and thymocytes and splenocytes 
visualized under a light microscope using the Trypan Blue exclusion test, and counted with a hemocytometer.
aNumber of animals in each group.
bMean ± S.E.M.
*Significant @ p < .025. **Significant @ p < .005. ***Significant @ p < .001.Reproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
Page 7 of 11
(page number not for citation purposes)
E2- and T-induced changes in thymocyte levels of female B6A mice Figure 2
E2- and T-induced changes in thymocyte levels of female B6A mice. Animals in (A) were given 3 daily sc injections of 
10 μl sesame oil:ethanol (9:1; v:v) [vehicle] with or without 20 μg E2, starting at 5 days of age. They were killed at 8, 9, 10, 11, 
and 12 days of age. Each data-point consists of the average number of viable thymocytes isolated from thymuses of 2 animals. 
In (B) the animals were given 4 daily injections of either 10 μl vehicle, or vehicle containing 20 μg T, starting at 0 days of age. 
They were killed at 5, 7, 9, and 12 days of age. Five animals were used for each data-point. Thymocytes were visualized using 
the Trypan Blue Exclusion Test and counted in a hemocytometer.
A
BReproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
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causes both ovarian dysgenesis and follicular cysts. E2
injection at point C prevents development of TReg CD8 cells,
and follicular cysts are produced. Ovarian dysgenesis does
not occur because TReg CD4 cells are produced by the
medulla prior to E2 intervention. Shown in study 1 (Table
1), ovaries of mice in Treatment 5 have the same patholo-
gies as described for the Tx-3 + E2 group (dysgenic, dys-
genic + cystic, and cystic) [12]; whereas, the ovaries of
Treatment 7 animals are normal. This indicates that the
infusate from 7-day-old donors, given to Treatment 5
mice lacked TReg CD4 and TReg CD8 cells; whereas, the infu-
sate from adult donors, given to Treatment 7 animals con-
tained TReg CD4 and TReg CD8 cells. These same results
occurred in Treatment 4 and Treatment 6 animals, and for
the same reason.
An examination of the literature indicates a strong likeli-
hood of thymus involvement in estrogen and/or testoster-
one-induced anovulation in other animal species. For
example, Kincl et al. [24,25] reported that anovulation in
E2- and T-injected female rats could be prevented by thy-
mocyte infusion. Notably, only thymocytes from adult
donors were effective. Thymocytes from 5-day-old ani-
mals did not prevent anovulation. In primates the thymus
undergoes its final development prenatally [7]. Steroid
action would thus occur in utero. This could explain why
injections of testosterone propionate (TP) given to preg-
nant rhesus monkeys on gestational day's 40–55, pro-
duces anovulatory female offspring [26,27]. The female
offspring have enlarged ovaries with multiple small folli-
cles; an elevated LH/FSH ratio; and, high levels of serum
17αOH-progesterone and testosterone.
Additional evidence of steroid influence in utero is
detailed in reports of the consequences of using DES in
pregnant women [28-35]. Prescribed from the 1940s until
1971, DES was banned by the FDA due to the large
number of reproductive problems in daughters exposed in
utero. Problems included an increased rate of primary
infertility, oligomenhorrhea, amenorrhea, high levels of
androstenedione and testosterone, facial hirsutism, and
an elevated LH/FSH ratio. These symptoms are all associ-
ated with the formation of cysts [36,37]. Notably, expo-
sure to DES on gestational weeks 9 through 12 produced
the highest rate of infertility [35]. This timeframe is coin-
cident with the final developmental stages of the thymus
[7].
The identity of the self-antigen(s) that CD8+
Autoreactive T
cells regard as nonself, is at present, a matter for conjec-
ture. MECs synthesize approximately 300 ectopic tissue
proteins [20]. At least two are involved in autoimmune
disease. A peptide epitope of insulin initiates CD8+
Autoreac-
tive T cell destruction of pancreatic β cells [38], and zona
pellucida glycoprotein 3 (ZP3) is implicated as the self-
antigen involved in ovarian dysgenesis [39]. Synthesized
in the ovary by the oocyte and granulosa cells [40], ZP3 is
a prime candidate for the self-antigen involved in the for-
mation of follicular cysts. Destruction of granulosa cells
by CD8+
Autoreactive T cells would seriously impair the folli-
cle's capacity to synthesize estrogen. Restoration of this
ability might explain why injections of FSH cause ovula-
tion in clomiphene-resistant PCOS women without inter-
vention by either exogenous LH or hCG [41].
In conclusion: we have proposed that follicular cysts
formed in a popular animal model of PCOS represent an
autoimmune disease initiated by steroid administration.
An increased incidence of autoimmune disease in DES-
exposed women [42], lends further support for the
autoimmune nature of PCOS. As maternally derived
androgens and estrogens diffusing into the fetal area are
limited by the amnion [43], and are normally at nano-
gram levels, it is unlikely that this source of steroid causes
PCOS. The reproductive problems observed with DES
came from milligram levels [44]. Potential sources of ster-
oids at this level are phytoestrogens, contained in food
supplements and ingested by some pregnant women. The
Table 3: The effect of injecting female B6A mice with estrogen at 5–7 days of age on thymocyte and splenocyte numbers at adulthood.
Age and Treatment Thymocytes × 106 Splenocytes × 106
60-day-old, vehicle-injected [8]a 72.5 ± 12.0b -----
60-day-old, estrogen-injected [14] 43.0 ± 4.8* -----
100-day-old, vehicle-injected [10] 122.6 ± 19.1 22.0 ± 3.7
100-day-old, estrogen-injected [14] 57.0 ± 7.8** 52.5 ± 5.4*
150-day-old, vehicle-injected [18] ----- 20.4 ± 1.6
150-day-old, estrogen-injected [27] ----- 50.2 + 5.8***
Beginning at 5 days of age, mice were given 3 daily sc injections of 10 μl sesame oil: ethanol (9:1; v:v) {vehicle), with and without 20 μg estradiol-17β. 
In one study the mice were killed at 60 days of age, thymuses removed, and thymocytes visualized under a light microscope using the Trypan Blue 
exclusion test and counted in a hemocytometer. In a second study, the mice were killed at 100 days of age, and spleens also removed, and both 
splenocytes and thymocytes isolated and counted. In a third study, the mice were killed at 150 days of age and only splenocytes were counted.
aNumber of animals in each group.
bMean ± S.E.M.
*Significant at p < .05. **Significant at p < .01. ***Significant at p < .001.Reproductive Biology and Endocrinology 2009, 7:47 http://www.rbej.com/content/7/1/47
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Centers for Disease Control and Prevention, for example,
report that 10% of representative samples of women in
the United States contain urinary levels in the milligram
range, of phytoestrogens found in flax seed [45]. Flax seed
and soy bean products cause reproductive problems in
female rats [46] and mice [47], and mice suffer thymocyte
loss and thymic atrophy when given genistein, the phy-
toestrogen contained in soy beans [47]. Our future
research will determine whether or not phytoestrogens
cause anovulation and follicular cysts when administered
to female mice during the thymus' critical period. We will
also be investigating the impact of adrenal corticoids.
While the bulk of this paper has concentrated on the role
of gonadal steroids, the observation that adrenal steroids
diminish thymic/spleen weight and numbers of thymo-
cytes/splenocytes (Table 2), and can instigate cyst forma-
tion [6], raises the possibility that severe stress during
pregnancy may be a factor in PCOS development.
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Proposed pathway for the discharge of immature thymocytes from thymuses of E2-injected female B6A mice Figure 3
Proposed pathway for the discharge of immature thymocytes from thymuses of E2-injected female B6A mice. 
The top diagram (A) depicts the typical thymocyte maturation pathway, beginning with the sub-capsular entry of prothymo-
cytes into the cortex and the expression of Thy-1. Maturation continues through CD3-CD4-CD8- triple negative (TN) stages 
and the development of the T cell receptor (TcR). Subsequent expression of CD3 produces CD3+CD4- CD8- double negative 
(DN) cells with αβ TcR. After expression of CD4 and CD8, the CD4+CD8+ double positive (DP) cells undergo the process of 
positive selection. Surviving DP cells pass through the corticomedullary junction into the medulla. Here, they are transformed 
into CD4+ (SP) and CD8+ (SP) T cells, and in the process, autoreactive T cells are eliminated. Mature SP T cells then exit the 
thymus at the corticomedullary junction. The bottom diagram (B) shows how the E2-induced increase in vascular permeability 
is proposed to affect thymocyte maturation. Thymocytes, rather than expressing CD4+ and CD8+ and continuing into the 
medulla, exit the thymus at the corticomedullary junction. Maturation into SP T cells then takes place in the sinusoids of the 
liver.
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